Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Liabilities (2019 - 2025)

C4 Therapeutics' Total Liabilities history spans 7 years, with the latest figure at $102.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 23.3% year-over-year to $102.5 million; the TTM value through Dec 2025 reached $102.5 million, down 23.3%, while the annual FY2025 figure was $102.5 million, 23.3% down from the prior year.
  • Total Liabilities reached $102.5 million in Q4 2025 per CCCC's latest filing, down from $111.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $151.0 million in Q1 2022 to a low of $102.5 million in Q4 2025.
  • Average Total Liabilities over 5 years is $127.8 million, with a median of $131.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: surged 36.86% in 2022, then dropped 23.3% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $117.2 million in 2021, then grew by 20.87% to $141.6 million in 2022, then decreased by 7.96% to $130.3 million in 2023, then rose by 2.52% to $133.6 million in 2024, then decreased by 23.3% to $102.5 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Total Liabilities are $102.5 million (Q4 2025), $111.1 million (Q3 2025), and $122.5 million (Q2 2025).